Gilead Sciences Inc/ US3755581036 /
16/04/2024 16:04:06 | Chg. - | Volume | Bid17:30:00 | Ask17:30:00 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
63.25EUR | - | 4 Turnover: 253 |
-Bid Size: - | -Ask Size: - | 75.36 bill.EUR | - | - |
GlobeNewswire
22/05
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire
14/05
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
09/05
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
09/05
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
08/05
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
08/05
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
29/04
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
19/04
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
10/04
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
02/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
01/04
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...
GlobeNewswire
28/03
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
28/03
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GlobeNewswire
22/03
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
18/03
CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards
GlobeNewswire
11/03
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire
29/02
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...
GlobeNewswire
29/02
Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...
GlobeNewswire
28/02
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...